Compare iShares Core Growth Allocation ETF (AOR) vs Nuwellis Inc (NUWE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
iShares Core Growth Allocation ETF vs Nuwellis Inc — how do they compare? iShares Core Growth Allocation ETF trades at $69.09, while Nuwellis Inc trades at $2.94 (market cap $1.10M). The key difference: iShares Core Growth Allocation ETF is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals.
| AOR | NUWE | |
|---|---|---|
52-Week High | $69.85 | $558.26 |
52-Week Low | $61.00 | $2.87 |
Market Cap | — | $1.10M |
Sector | — | Technology |
Enterprise Value | — | -$713.47K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
The iShares Core Growth Allocation ETF (AOR) trades at $69.10, up 0.25% on the day, with a bearish technical signal from moving averages and neutral oscillators. The fund maintains a fixed 60/40 stock/bond allocation, rebalanced semiannually, with a low 0.20% expense ratio. Recent news highlights its role as a core holding but notes underperformance versus the S&P 500 over a decade.
Outlook: AOR offers diversified, low-cost exposure but faces headwinds from equity-bond correlation shifts. Risks include interest rate sensitivity and competition from pure equity funds. Analyst sentiment is mixed, balancing simplicity against relative returns.
NUWE trades at $3.04, up 5.56% today, but faces bearish technical signals with oversold RSI readings. The company reported a net loss of $17.52M in 2025 with negative margins, though recent earnings beat expectations in two of the last three quarters. A reverse stock split was executed in June 2026, and new CEO Mike McCormick is focusing on pediatric market expansion.
Outlook remains challenging due to persistent losses and high cash burn, but strategic initiatives in pediatric cardiorenal care and recent FDA engagement offer potential growth. Risks include financial sustainability and competitive pressures. Analyst sentiment is split evenly between Buy and Hold.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core Growth Allocation ETF
The fund is a fund of funds and seeks its investment objective by investing primarily in underlying funds that themselves seek investment results corresponding to their own respective underlying indexes. It generally will invest at least 80% of its assets in the component securities of its underlying index. The index measures the performance of the S&P Dow Jones Indices LLC proprietary allocation model.
Read more on AOR →About Nuwellis Inc
Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →
